XBIT · XBRL financial data

XBiotech financial statements, every fiscal year

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (XBIT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cost of goods and services sold	34,548	5,820	651	0	—	—
Gross profit	9,449	12,574	3,359	0	—	—
Research and development	9,527	28,268	31,544	32,848	37,757	47,390
General and administrative	18,198	9,388	6,305	4,662	4,714	8,295
Total operating expenses	27,725	37,656	37,849	37,510	42,471	—
Operating income (loss)	(18,276)	(25,082)	(34,490)	(37,510)	(42,471)	(55,685)
Other income (expense)	(503)	(132)	(121)	883	432	1,456
Income tax expense (benefit)	(1,606)	(8,044)	(688)	244	(32)	235
Net income (loss)	(11,221)	(17,414)	(32,900)	(24,557)	(38,531)	(45,540)
Earnings per share, basic USD per share	(0.36)	(0.58)	(1.08)	(0.81)	(1.26)	(1.49)
Earnings per share, diluted USD per share	(0.36)	(0.58)	(1.08)	(0.81)	(1.26)	(1.49)
Weighted average shares, basic thousands of shares	30,823	30,043	30,439	30,438	30,461	30,488
Weighted average shares, diluted thousands of shares	30,823	30,043	30,439	30,438	30,461	30,488

Fiscal years (XBIT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	237,366	236,983	157,306	200,023	172,677	125,551
Short-term investments	—	0	60,172	0	—	—
Accounts receivable	4,113	0	1,216	860	700	—
Prepaid and other current assets	582	934	601	760	1,032	1,042
Total current assets	325,875	246,870	219,843	201,718	174,567	126,953
Property and equipment, net	27,336	28,307	26,260	24,897	24,526	23,129
Total assets	353,744	275,177	246,103	226,615	199,093	150,082
Accounts payable	2,491	2,069	2,408	2,516	2,223	1,535
Accrued liabilities	1,351	1,374	1,603	3,501	2,632	6,318
Total current liabilities	3,984	3,453	4,066	6,100	15,105	7,929
Total liabilities	5,105	5,792	5,701	7,769	16,825	9,732
Retained earnings (accumulated deficit)	97,568	5,151	(27,749)	(52,306)	(90,837)	(136,377)
Total stockholders' equity	348,639	269,385	240,402	218,846	182,268	140,350
Total liabilities and equity	353,744	275,177	246,103	226,615	199,093	150,082
Common shares outstanding (cover page) thousands of shares	29,459	30,439	30,439	30,451	30,488	30,488

Fiscal years (XBIT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(11,221)	(17,414)	(32,900)	(24,557)	(38,531)	(45,540)
Stock-based compensation	12,581	4,463	5,062	3,262	1,753	3,622
Net cash from operating activities	(65,149)	69,445	(14,824)	(18,725)	(30,963)	(39,920)
Purchases of property and equipment	3,727	3,525	585	362	1,304	289
Net cash from investing activities	(3,727)	(3,525)	(63,892)	61,497	(1,304)	(289)
Proceeds from issuing common stock	10,300	8,000	—	5	—	—
Share repurchases	—	—	0	14	0	—
Dividends paid	0	75,003	0	—	—	—
Net cash from financing activities	(409,724)	(67,008)	0	(9)	10,450	(10,250)
Net change in cash	(477,228)	(383)	(79,677)	42,717	(27,346)	(47,126)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
XBiotech	109,528	not reported	(4,515)*	30.5M	24.3 quarters	Q2 FY26 10-QJun 30, 2026
Oramed Pharmaceuticals	15,245	not reported	(200)*	41.6M	80.5 quarters	Q2 FY26 10-QJun 30, 2026
Inovio Pharmaceuticals	31,526	0	(18,047)*	103.4M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Macrogenics	113,907	32,832	(40,748)*	63.7M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Volitionrx	2,800	399	(5,160)*	13.6M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Gyre Therapeutics	43,287	29,105	(16,728)*	111.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Elicio Therapeutics	23,480	not reported	(8,165)*	26.3M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Coherus Oncology	82,923	not reported	(62,090)*	154.5M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Oncolytics Biotech	4,115	not reported	(8,138)*	127.5M	0.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.